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xtracellular matrix mineralization (ECMM) is a physi-
ologic process in the skeleton and in teeth and a
pathologic one in other organs. The molecular mecha-
nisms controlling ECMM are poorly understood. Inactivation
of 
 
Matrix gla protein
 
 (
 
Mgp
 
) revealed that MGP is an inhibitor
of ECMM. The fact that MGP is present in the general
circulation raises the question of whether ECMM is regulated
locally and/or systemically. Here, we show that restoration
of 
 
Mgp
 
 expression in arteries rescues the arterial mineraliza-
tion phenotype of 
 
Mgp
 
 
 
/
 
 
 
 mice, whereas its expression
E
 
in osteoblasts prevents bone mineralization. In contrast,
raising the serum level of MGP does not affect mineralization
of any ECM. In vivo mutagenesis experiments show that
the anti-ECMM function of MGP requires four amino acids
which are 
 
 
 
-carboxylated (gla residues). Surprisingly, another
gla protein speciﬁc to bone and teeth (osteocalcin) does
not display the anti-ECMM function of MGP. These results
indicate that ECMM is regulated locally in animals and
uncover a striking disparity of function between proteins
sharing identical structural motifs.
 
Introduction
 
ECM mineralization (ECMM) is a physiologic process in
bone, teeth, and hypertrophic cartilage, whereas in other
locations it must be inhibited. To date, few proteins acting
as inhibitors of ECMM have been identified through mouse
and human genetic studies. They include: Ank, a transmem-
brane protein controlling extracellular export of pyrophosphate,
a small molecule that itself inhibits ECMM; NPPS, an
ectoenzyme also generating pyrophosphate extracellularly;
matrix gla protein (MGP), a mineral-binding protein of the
ECM; and fetuin, a circulating protein that accumulates in
bone ECM (Jahnen-Dechent et al., 1997; Luo et al., 1997;
Okawa et al., 1998; Nakamura et al., 1999; Hagmann,
2000; Ho et al., 2000; Nurnberg et al., 2001; Schafer et al.,
2003). Understanding at the molecular level how each of
these proteins inhibits ECMM is a prerequisite to better
understanding how ectopic ECMM develops, such as that
observed in atherosclerosis or in osteoarthritis. Elucidation
of the mechanisms behind protein inhibition of ECMM
may lead eventually to the identification of novel therapeutic
strategies for the treatment of these diseases.
With the long-term goal of understanding how ECMM is
prevented in some tissues, whereas favored in others, our
laboratory has embarked on a detailed study of the functions
and mechanisms of action of proteins containing gla (or
 
 
 
-carboxylated glutamic acid) residues (Pudota et al., 2000;
Bandyopadhyay et al., 2002). This posttranslational modifi-
cation confers to proteins a high affinity for hydroxyapatite
crystals, the major mineral crystal present in mineralized
ECMs (Romberg et al., 1986; Roy and Nishimoto, 2002;
Hoang et al., 2003). We focused our work on two gla residue-
containing proteins, namely MGP and bone gla protein
(BGP or osteocalcin), the latter being a protein long thought
to be involved in bone ECMM (Price et al., 1976, 1983;
Celeste et al., 1986). 
 
Mgp
 
 is expressed in vascular smooth
muscle cells (VSMCs) and in chondrocytes but not in osteo-
blasts, whereas 
 
Osteocalcin
 
 is expressed in osteoblasts and
odontoblasts only (Ducy and Karsenty, 1995; Luo et al.,
1995). In addition, both MGP and osteocalcin are circulating
proteins (Lian et al., 1987; Ismail et al., 1988; Price et al.,
2003). Consistent with the pattern of 
 
Mgp
 
 expression, MGP-
deficient mice develop abnormal ECMM in their arteries and
growth plate cartilage establishing that MGP is an inhibitor
of ECMM in the vicinity of the cells expressing it (Luo et al.,
1997). In contrast, osteocalcin-deficient mice did not have
any detectable defect of bone ECMM indicating that osteo-
calcin is not required for bone mineralization (Ducy et al.,
1996). This latter experiment did not address however,
whether osteocalcin, like MGP, could inhibit ECMM.
 
Address correspondence to Gerard Karsenty, Baylor College of Medicine,
One Baylor Plaza, Rm. S921, Houston, TX 77030. Tel.: (713) 798-5489.
Fax: (713) 798-1530. email: karsenty@bcm.tmc.edu
Key words: MGP; osteocalcin; ECM; mineralization; local regulation
 
Abbreviations used in this paper: ECMM, ECM mineralization; MGP,
matrix gla protein; VSMC, vascular smooth muscle cell; WT, wild-type. 
626 The Journal of Cell Biology 
 
|
 
 
 
Volume 165, Number 5, 2004
 
The striking differences between MGP and osteocalcin
functions already revealed by gene deletion experiments
(Ducy et al., 1996; Luo et al., 1997), together with the fact
that these proteins are circulating systemically raised a series
of questions: first, do these proteins act only after local secre-
tion and/or do they act systemically by reaching various tis-
sues through the circulation? This is an important question
as mice deficient in fetuin, a circulating protein, develop ec-
topic ECMM when fed a high calcium and high phosphorus
diet (Schafer et al., 2003). Second, can we identify in vivo
the residues in MGP critical for its anti-ECMM function?
Lastly, because loss of function experiments failed to un-
cover a function for osteocalcin during ECMM, could gain
of function experiments help to provide definitive informa-
tion on whether osteocalcin is involved in ECMM?
To address these questions, we used MGP-deficient mice
and other transgenics to assess the vascular ECMM by gla-
containing proteins, and to assess the influence of these pro-
teins on bone mineralization. Our results are consistent with
the hypothesis whereby inhibitors of ECMM act locally and
not systemically. They also demonstrate that osteocalcin does
not carry out the anti-ECMM function of MGP in vivo.
 
Results and discussion
 
Generation of transgenic mice
 
To study the roles of MGP and osteocalcin during ECMM,
we generated several mouse models expressing, in a cell-spe-
cific manner, wild-type (WT) or mutated protein
 
s
 
 (Fig. 1,
A–E). We used a 
 
SM22
 
 
 
 promoter fragment to drive their
expression specifically in VSMCs, whereas liver-specific
expression was achieved by using the promoter of the 
 
apo-
lipoprotein E (ApoE)
 
 gene and its liver-specific enhancer
(Simonet et al., 1993; Solway et al., 1995). To achieve os-
teoblast-specific expression, we used the 2.3-kb promoter
fragment of the 
 
 
 
1(I) collagen
 
 gene (Rossert et al., 1995). In
each case, we obtained at least two different lines expressing
the transgene of interest and we verified cell- or tissue-specific
expression for each transgene (Fig. 1, A–E). 
 
SM22
 
 
 
-Mgp,
ApoE-Mgp, SM22
 
 
 
-Osteocalcin
 
, and 
 
 
 
1(I)Col-Osteocalcin
 
transgenics had no metabolic or histological abnormalities.
In particular, they had normally mineralized bone and no
sign of ectopic ECMM (Table I and not depicted). These
various transgenic mice were then used for subsequent ex-
periments presented below.
 
Rescue of arterial but not of cartilage phenotype in 
Mgp
 
 
 
/
 
 
 
; SM22
 
 
 
-Mgp mice
 
SM22
 
 
 
-
 
Mgp
 
 mice had no phenotypic abnormalities and se-
rum PTH, phosphate and calcium levels were normal. To
test if this transgene could rescue the arterial phenotype
of 
 
Mgp
 
 
 
/
 
 
 
 mice, we intercrossed 
 
SM22
 
 
 
-
 
Mgp
 
 mice with
 
Mgp
 
 
 
/
 
 
 
 mice to obtain 
 
Mgp
 
 
 
/
 
 
 
; 
 
SM22
 
 
 
-
 
Mgp
 
 mice. WT,
 
Mgp
 
 
 
/
 
 
 
 and Mgp
 
 
 
/
 
 
 
; SM22
 
 
 
-Mgp
 
 mice were analyzed at
4 wk old, the age at which most 
 
Mgp
 
 
 
/
 
 
 
 mice die due to
vascular rupture and hemorrhaging, by Alizarin red staining
of skeletal preparations and histological analyses (Luo et al.,
1997). Alizarin red staining of skeletal preparations failed to
detect any abnormal mineralization of the aorta or of any ar-
teries in 
 
Mgp
 
 
 
/
 
 
 
; SM22
 
 
 
-Mgp
 
 mice at that age or at 6 mo
old (Fig. 2 A and not depicted). Accordingly, histological ex-
amination using von Kossa staining for mineral deposits
failed to detect any ECMM in the arteries of 
 
Mgp
 
 
 
/
 
 
 
;
SM22
 
 
 
-
 
Mgp
 
 mice at 4 or 24 wk old (Fig. 2 B and not de-
picted). In contrast, mineralization of cartilage, an avascular
tissue, was not prevented in 
 
Mgp
 
 
 
/
 
 
 
; SM22
 
 
 
-
 
Mgp
 
 mice
(Fig. 2 D). Thus, reintroducing MGP in VSMCs could res-
cue only the arterial phenotype of MGP-deficient mice.
Figure 1. Transgene expression analysis. Schematic representation 
of the transgene constructs (left), transgene detection by PCR (middle), 
and Northern blot analysis showing tissue-specific expression (right) 
of SM22 -Mgp (A),  1(I)Col-Mgp (B), ApoE-Mgp (C), SM22 -
Osteocalcin (D), and  1(I)Col-Osteocalcin (E) transgenes. The letter 
E on transgenes represents  -carboxylated glutamic acid residues.
 
Table I. 
 
Serum phosphate (Pi), calcium (Ca), and parathyroid hormone (PTH) concentrations in the transgenic mice
 
Transgenic mice [Pi] mg/dL (
 
 
 
M
 
) [Ca]
 
total
 
 mg/dL (
 
 
 
M
 
) [PTH] pg/mL (
 
 
 
M
 
)
 
SM22
 
 
 
-Mgp
 
7.91 (0.38) 9.58 (0.23) 34.76 (1.38)
 
ApoE-Mgp
 
7.05 (0.29) 10.20 (0.20) 29.67 (5.24)
 
 
 
1(I)Col-Mgp
 
7.39 (0.06) 9.91 (0.08) 38.11 (7.56)
 
SM22
 
 
 
-Osteocalcin
 
7.35 (0.25) 10.00 (0.09) 25.95 (0.54)
 
 
 
1(I)Col-Osteocalcin
 
8.01 (0.19) 10.37 (0.15) 31.28 (4.47)
WT 7.89 (0.92) 10.37 (0.06) 29.02 (5.30)
SEM (
 
 
 
M
 
) values are presented in the parentheses. 
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Systemic presence of MGP does not rescue the 
phenotype of MGP
 
 
 
/
 
 
 
 mice
 
Because MGP is found in the general circulation where it
forms a complex with small mineral nuclei and other circu-
lating proteins (Price et al., 2003), the question arises as to
its mode of action. Is MGP acting locally in the vicinity of
the cells synthesizing it and/or is it using blood transport as
a means to inhibit ECMM in locations where it is not syn-
thesized? To address this question, we used the promoter
and liver-specific enhancer of 
 
ApoE
 
 to achieve ectopic ex-
pression of 
 
Mgp
 
 in liver and thereby in blood. Systemic
presence of MGP in these mice was confirmed by dot blot
experiments using a polyclonal serum raised against a
COOH-terminal MGP peptide. Using this assay, 
 
ApoE-
Mgp
 
 transgenics showed a 6–10-fold increase of serum
MGP in comparison to their WT littermates (Fig. 3 A). To
demonstrate that MGP originating from the transgene has
the ability to inhibit mineralization we cultured WT osteo-
blasts in the presence of either WT or 
 
ApoE-Mgp
 
 mouse se-
rum. Whereas osteoblasts cultured in the presence of WT
serum formed nodules that mineralized, those cultured in
the presence of 
 
ApoE-Mgp
 
 serum showed a marked reduc-
tion of mineralization (Fig. 3 B). This was not due to an
absence of osteoblastic nodules because alkaline phos-
phatase staining showed a comparable number of nodules
in both culture conditions (Fig. 3 B). Thus, MGP originat-
ing from this transgene has conserved its antimineraliza-
tion function.
 
ApoE-Mgp
 
 mice had no phenotypic abnormalities and had
normal serum PTH, calcium, and phosphate levels (Table I
and not depicted). They were intercrossed with 
 
Mgp
 
 
 
/
 
 
 
mice to eventually generate 
 
Mgp
 
 
 
/
 
 
 
; 
 
ApoE-Mgp
 
 mice. At 4
wk old, Alizarin red staining of skeletal preparations revealed
that 
 
Mgp
 
 
 
/
 
 
 
; ApoE-Mgp mice developed mineralization
of aorta similar to that observed in Mgp /  mice (Fig. 3
C). Likewise, histological analysis showed the presence of
ECMM in Mgp / ; ApoE-Mgp arteries (Fig. 3 D). These
results provided the first evidence that, MGP acts locally not
systemically to prevent ECMM.
To extend these observations, we asked whether bone
mineralization could be affected by either local or systemic
expression of Mgp. To that end, we studied bone mineraliza-
tion at 4 wk old in WT, ApoE-Mgp, and in  1(I)Col-Mgp
mice that express Mgp only in osteoblasts (Fig. 1 B). Skeletal
preparations of 10-d-old skulls showed no mineralization
defect in ApoE-Mgp mice, whereas a severe decrease in in-
tramembranous bone mineralization was observed in  1(I)
Col-Mgp mice (Fig. 3 E). Likewise, histological analysis of
vertebrae of ApoE-Mgp mice failed to show any increase in
unmineralized bone, whereas histological analysis of verte-
brae of  1(I)Col-Mgp mice showed a marked, i.e., 8–12-
fold, increase of unmineralized bone tissue (Fig. 3 F). When
together, the analyses of Mgp / ; SM22 -Mgp, ApoE-Mgp,
and  1(I)Col-Mgp mice establish that, in animals fed a nor-
mal diet, MGP inhibits ECMM locally and not systemically.
MGP and osteocalcin do not share an antimineralization 
function despite structural similarities
The osteoidosis, i.e., increase in unmineralized bone ECM,
observed in the  1(I)Col-Mgp mice provided us with an in
vivo model to test the function of the gla residues within
MGP and other proteins. In this context, we generated
transgenic mice that produced two distinct mutated forms
of MGP in osteoblasts. In MGP mutant1 (MGPm1), three
of the four glutamic acid residues present in the mouse pro-
tein were replaced by aspartic acid residues. In MGP
mutant2 (MGPm2) all four glutamic acid residues undergo-
ing  -carboxylation were replaced by aspartic acid resi-
dues.  Histological analysis performed in 4-wk-old mice
failed to detect any evidence of osteoidosis in the  1(I)Col-
Mgpm2 mice, whereas osteoidosis was considerably milder
in  1(I)Col-Mgpm1 mice than in  1(I)Col-Mgp (Fig. 4 C).
These results establish that the gla residues are required for
MGP antimineralization function.
Figure 2. VSMC-specific expression of Mgp 
prevents arterial mineralization of Mgp /  mice. 
(A) Skeletal preparation of the thoracic aorta from a 
4-wk-old Mgp / ; SM22 -Mgp mouse shows the 
absence of mineral-specific Alizarin red staining, 
which is present in Mgp /  aorta (arrow). (B) von 
Kossa staining of a 4-wk-old Mgp / ; SM22 -Mgp 
aorta section shows complete lack of mineral 
deposition, whereas an Mgp /  aorta section 
shows mineral depositions (arrow) along the elastic 
lamina. (C) Mgp / ; SM22 -Mgp mice have a 
normal life span. (D) VSMC-specific expression of 
Mgp failed to prevent the progressive mineralization 
of the growth plate cartilage in these mice.628 The Journal of Cell Biology | Volume 165, Number 5, 2004
The demonstration of the functional importance of gla
residues in MGP leads to the question of whether other gla-
containing proteins are also inhibitors of ECMM. Osteo-
calcin is the most abundant gla protein synthesized in the
skeleton, yet its deletion in mice failed to show impaired
ECMM (Ducy et al., 1996). However, because this experi-
ment could not assess whether osteocalcin, like MGP, could
act as an inhibitor of ECMM, we subsequently performed
here gain of function and ectopic expression experiments.
SM22 -Osteocalcin mice did not show any metabolic or
histological abnormalities (Table I and not depicted) despite
a six- to eightfold increase in serum osteocalcin indicating
efficient transcription/translation of the transgene (Fig. 5
A).  SM22 -Osteocalcin mice were then intercrossed with
Mgp /  mice to obtain Mgp / ; SM22 -Osteocalcin
mice. Surprisingly, these latter mutant mice did not survive
past 2 mo old and possessed the phenotype of Mgp / 
mice (unpublished data). Indeed, Alizarin red staining of
skeletal preparations and histological analysis showed that at
1 mo old the aorta of Mgp / ; SM22 -Osteocalcin was
fully mineralized (Fig. 5, B and C). This result indicates that
unlike MGP and despite the presence of three gla residues,
osteocalcin cannot inhibit ECMM in arteries. Alternatively,
it could mean that this function of osteocalcin could not be
incurred outside bone, its physiological site of expression.
To test this possibility, we generated transgenic mice overex-
pressing Osteocalcin in osteoblasts under the control of the
 1(I) collagen promoter. Again, unlike what we observed in
 1(I)Col-Mgp transgenic mice,  1(I)Col-Osteocalcin mice
had normally mineralized bone. In particular, they had a
normal osteoid volume relative to total bone volume (Fig. 5
D). Together, the results of these two experiments indicate
that despite the presence of gla residues, osteocalcin is not an
inhibitor of ECMM in vivo. Based on the gain of function
experiments presented here and on the loss of function ex-
periments described previously it appears that the gla resi-
dues do not affect MGP and osteocalcin functions in the
same way. Our results raise the hypothesis that, as it is the
case for thrombin, only decarboxylated osteocalcin may have
a function (Furie and Furie, 1988). Consistent with this hy-
pothesis, it was shown recently that serum level of decarbox-
ylated osteocalcin is a reliable indicator of the severity of os-
teoporosis in postmenopausal women (Szulc et al., 1996).
In summary, using genetic and in vivo bioassay models of
physiologic (bone) and pathologic (arterial) ECMM, we
Figure 3. Increased serum MGP level does not prevent ECMM in 
vivo. (A) Dot blot analysis shows a 6–10-fold increase of MGP serum 
level in ApoE-Mgp mice in comparison to their WT littermates. 
The error bars represent SDs of three independent measurements. 
(B) ApoE-Mgp serum prevents in vitro mineralization of primary 
osteoblast culture, whereas WT serum does not (top). Note that 
nodule formation is comparable under both conditions (bottom). 
Skeletal preparation of the thoracic aorta (C) and von Kossa staining 
of an aorta section (D) from a 4-wk-old Mgp / ; ApoE-Mgp mouse 
show mineral deposition as seen in Mgp /  mice. The arrows in C 
indicate mineralized aortae. (E) Skeletal preparations of 10-d-old 
ApoE-Mgp skulls show normal ECM mineralization, whereas it is 
severely affected in  1(I)Col-Mgp skulls. (F) von Kossa and van 
Gieson staining show normal bone mineralization in a 4-wk-old 
ApoE-Mgp vertebra and a 12-fold increase of unmineralized bone 
(arrow) in a 4-wk-old  1(I)Col-Mgp vertebra.
Figure 4. Gla residues are required for MGP function. Schematic 
representation of the transgene constructs (left), transgene detection 
by PCR (middle), and Northern blot analysis showing tissue-specific 
expression of the transgenes (right) in  1(I)Col-Mgpm1 (A) and 
 1(I)Col-Mgpm2 (B) transgenics. Letters E and D on transgenes 
represent  -carboxylated glutamic acid residues and mutated aspartic 
acid residues, respectively. (C) von Kossa and van Gieson staining 
of vertebra sections show a threefold increase of unmineralized 
bone (arrow) in a 4-wk-old  1(I)Col-Mgpm1 mouse, whereas bone 
mineralization is largely unaffected in an  1(I)Col-Mgm2 mouse.Local regulation of ECM mineralization | Murshed et al. 629
demonstrate that inhibition of ECMM by proteins is ex-
erted locally and not systemically. They also uncover great
functional disparity between proteins sharing identical func-
tional motifs thought to be pivotal in controlling ECMM.
Indeed, our mutagenesis experiments establish that the gla
residues are required for MGP inhibition of ECMM func-
tion, yet gla residue-containing osteocalcin cannot inhibit
ECMM. This observation again underscores the importance
of in vivo tests for protein function even when their struc-
ture might suggest an obvious function. The observation
that MGP can inhibit ECMM in arteries and bone suggests
that the function of inhibitors of ECMM does not overtly
depend on the composition of a given ECM but rather de-
pends on the expression of these inhibitors. The similarity of
function of MGP in bone and in preventing arterial ECMM
implies also that if one can elucidate the molecular bases for
the spatial restriction of ECMM to bone then this informa-
tion could possibly be used to prevent ectopic mineralization
in diseases of arteries and joints.
Materials and methods
DNA constructs
DNA constructs for VSMCs and osteoblast-specific expressions of Mgp
transgenes were generated using a plasmid (pSMS4) containing Mgp ORF
with a downstream SV40 polyadenylation signal. To generate pSM22 -
Mgp, a 3-kb SM22  promoter fragment was inserted at a XhoI site up-
stream to the Mgp ORF in pSMS4. Similarly, to generate p 1(I)Col-Mgp, a
2.3-kb  1(I) collagen promoter fragment was inserted upstream to the Mgp
ORF. p 1(I)Col-Mgpm1 with three gla-encoding codons mutated to Asp
encoding codons was generated by PCR mutagenesis. The mutated ampli-
cons were digested by NcoI to replace the NcoI fragment of Mgp ORF in
pSMS4 and was followed by the insertion of a 2.3-kb  1(I) collagen pro-
moter at an upstream XhoI site. To generate p 1(I)Col-Mgpm2, the re-
maining gla encoding codon in p 1(I)Col-Mgpm1 construct was mutated
to an aspartic acid encoding codon by PCR mutagenesis. The mutated am-
plicon was digested by ClaI and PpuM1 to replace the ClaI and PpuMI di-
gested fragment of  1(I)Col-Mgpm1. pApoE-Mgp was generated by insert-
ing the Mgp ORF at a HpaI site of pLiv7 containing a 3-kb ApoE promoter
fragment, the first intron, polyadenylation signal, and a liver-specific en-
hancer (Simonet et al., 1993). To construct pSM22 -Osteocalcin, the com-
plete Osteocalcin ORF was first subcloned in pBlueScript (Stratagene).
The SV40 polyadenylation signal was introduced at a 3  XbaI site and the
3-kb SM22  promoter fragment was inserted at an upstream XhoI site.
p 1(I)Col-Osteocalcin was constructed by inserting the 2.3-kb  1(I) col-
lagen promoter fragment upstream to the Osteocalcin ORF and SV40 poly-
adenylation signal.
Mice
Generation of Mgp /  mice was described previously (Luo et al., 1997).
Transgenic founders were generated by pronuclear injection according to
standard techniques. All mice were maintained in a pathogen-free stan-
dard animal facility.
Genotyping and expression analysis
Genotypes were determined by PCR using isolated tail DNA. The follow-
ing sets of primers were used: for SM22 -Mgp transgene 5 -AAG-
GAAGGGTTTCAGGGTCCTG-3  and 5 -CGGGAAAGATGAGGAAGA-
AGGG-3 ; for  1(I)Col-Mgp,   1(I)Col-Mgpm1, and  1(I)Col-Mgpm2
transgenes 5 -CCAGGATGCCTGAAAGATTACTAGC-3  and 5 -CGG-
GAAAGATGAGGAAGAAGGG-3 ; for ApoE-Mgp transgene 5 -TTAGAG-
GAAATCACAGGGGGAGGC-3  and 5 -GGATCGCAACAAGCCTGC-
CTACGATATCAACAGAGATGC-3 ; for SM22 -Osteocalcin transgene 5 -
AAGGAAGGGTTTCAGGGTCCTG-3  and 5 -GGGGATCTGGGCTGGG-
GACTGAGG-3  and for  1(I)Col-Osteocalcin transgene 5 -CCAGGATGC-
CTGAAAGATTACTAGC-3  and 5 -GGGGATCTGGGCTGGGGACTG-
AGG-3 . For analysis of transgene expression, RNA was isolated as
previously described and analyzed by Northern blotting (Ausubel et al.,
1996). Probes used were SV40 and ApoE polyadenylation signals.
Primary osteoblast culture
WT osteoblasts were cultured in Alpha-MEM (Invitrogen) containing 10%
WT or ApoE-Mgp serum and supplemented by 100  g/ml ascorbic acid
(Sigma-Aldrich). After formation of osteoblastic nodules at 4 d, 5 mM
 -glycerophosphate (Sigma-Aldrich) was added to the culture medium and
cells were grown for another 4 d. Fresh medium was added in every 48 h.
von Kossa staining for mineral and alkaline phosphatase staining for osteo-
blasts were performed at the end of the culture period.
Skeletal preparation
Thoracic aorta together with vertebrae were dissected, fixed overnight in
100% ethanol, and stained in Alcian blue dye followed by Alizarin red so-
lution as described previously (Luo et al., 1997).
Histology
Vertebrae were fixed overnight in 4% PFA/PBS, embedded in methyl
methacrylate, sectioned (7  m), and stained by von Kossa and van Gieson.
Unmineralized bone was measured using Osteomeasure software (Osteo-
metrics Inc.). Aortas were fixed in 1% glutaraldehyde overnight, washed in
0.1 M sodium cacodylate buffer, serially dehydrated in ethanol, and em-
bedded in paraffin. 7- m sections were stained by von Kossa and coun-
terstained by Toluidine blue. Images were captured with a light micro-
scope (model DMLB; Leica) using a SPOT CCD camera, acquired with
SPOT software v2.1 (Diagnostic Instruments), and processed using Adobe
Photoshop
®.
Serum biochemistry
Serum calcium and phosphate were measured using commercially avail-
able kits (Sigma-Aldrich). PTH was measured using an ELISA kit for immu-
nodetection (Immunotopics). Dot blot analysis to detect serum MGP was
performed using a polyclonal rabbit serum raised against a COOH-termi-
nal MGP peptide (ERYAMVYGYNAAYNRYFRQRRGAKY). A commercially
available anti–rabbit antibody conjugated with HRP was used as a second-
ary antibody. HRP activity was detected by using standard protocols and
signal intensity on an imaging film was measured by NIH software for den-
sitometric analysis. Serum osteocalcin level was measured using an osteo-
calcin RIA kit (Biomedical Technologies Inc.).
We acknowledge Dr. P. Ducy from Baylor College of Medicine for very
useful suggestions.
Figure 5. Osteocalcin does not share antimineralization function 
of MGP. (A) Radioimmuno-assay shows a six- to eightfold increase 
of osteocalcin serum level in SM22 -Osteocalcin mice in comparison 
to their WT littermates. The error bars represent SDs of five indepen-
dent measurements. Skeletal preparation of the thoracic aorta (B) 
and von Kossa staining of aorta sections from a 4-wk-old Mgp / ; 
SM22 -Osteocalcin (C) mouse show mineral deposition as seen in 
Mgp /  mice. (D) von Kossa and van Gieson staining of a vertebra 
section show normal bone mineralization in 4-wk-old  1(I)Col-
Osteocalcin mice.630 The Journal of Cell Biology | Volume 165, Number 5, 2004
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